

Flash Note: Annual Financial Results 2025

(Unaudited Financial Data)

Strong EBITDA Growth of 48.9% and Significant Increase in Earnings Before Tax by 108,2%

Paiania, March 19, 2026 - Lavipharm S.A. informs the investment community of the key financial figures for fiscal year 2025.

Consolidated Sales from continuing operations, before Rebates & Clawbacks, amounted to Euro 70.03 million in 2025, compared to Euro 61.01 million during fiscal year 2024, reflecting an increase of 14.8%.

Gross profit amounted to Euro 30.31 million, compared to Euro 25.08 million in fiscal year 2024, representing an increase of 20.8%, while the gross profit margin improved by 2.17 percentage points.

Adjusted Consolidated Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) amounted to Euro 15.47 million, compared to Euro 10.39 million in FY 2024, representing an increase of 48.9%.

Adjusted Consolidated Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) from continuing operations amounted to Euro 14.52 million compared to Euro 9.96 million in FY 2024, representing a strong growth of 45.8%.

It should be noted that the Group's EBITDA was impacted by the amount of Euro 0.97 million due to the application of IFRS 2, which relates to the accounting treatment of the valuation of the Group's employee reward programs (Stock Option Plan and Stock Award Plan). This amount, while affecting the financial results, does not require any cash outflow by the Group. The corresponding amount for the year 2024 was Euro 1.36 million.

Earnings before Interest and Tax (EBIT) amounted to Euro 9.35 million, compared to Euro 5.54 million in fiscal year 2024, representing a significant increase of 68.8%.

Earnings before Tax amounted to Euro 7.50 million compared to Euro 3.60 million in fiscal year 2024, representing an increase of 108.2%.

Net profit attributable to the company's shareholders amounted to Euro 5.99 million, compared to Euro 8.98 million during fiscal year 2024. This decrease is attributable to the recognition in 2024 of deferred tax income amounting to Euro 6.3 million, resulting from the liquidation of the subsidiary company LAS S.A. Excluding this one-off tax income in FY 2024, net profit would have amounted to Euro 2.68 million, while the corresponding growth rate would have been 123,2%.

The net debt of the Lavipharm Group as of December 31, 2025, amounted to Euro 26.57 million, compared to Euro 28.23 million as of December 31, 2024.

"2025 was an outstanding year for Lavipharm, marked by strong sales growth and a significant improvement in profitability. These results validate our strategy and highlight the strength of our competitive positioning" noted **Telemaque Lavidas, Chief Executive Officer of Lavipharm.**

"Our performance is a direct result of disciplined execution and the commitment of our people. With a clear strategy and strong foundations, we are well positioned to accelerate growth and create long-term value," he added.

LAVIPHARM: KEY CONSOLIDATED FINANCIAL FIGURES 2025

(values in '000s)	2025	2024	Change %
Total Sales before Clawbacks-Rebates from continuing operations	70.028	61.009	14,8%
Clawbacks-Rebates	7.444	8.062	-7,67%
Net Sales	62.584	52.946	18,2%
Gross Profit	30.305	25.079	20,8%
Adjusted Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) from continuing and discontinued operations*	15.469	10.387	48,9%
Earnings before Interest and Tax (EBIT)	9.349	5.538	68,8%
Earnings before Tax	7.503	3.604	108,2%
Earnings after Tax from continuing operations	5.050	8.664	-41,7%
Gain from discontinued operations	940	315	198%
Earnings after Tax	5.990	8.979	-33,3%
Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) from ongoing and discontinued operations*	15.510	10.545	

***Adjustments for:**

Investment Property valuation	(41)	(157)
Bonds' valuation	(0)	(0)
Shares' valuation	(0)	(0)
Adjusted Earnings before Interest, Tax, Depreciation and Amortization and investment results (Adjusted EBITDA) from ongoing and discontinued operations	15.469	10.387

Earnings before Interest, Tax, Depreciation and Amortization and investment results (EBITDA) from discontinued operations	947	427
---	-----	-----

Lavipharm, listed on the Athens Stock Exchange since 1995 (LAVI), is a pharmaceutical company with a rich legacy in advancing patient care through pioneering healthcare solutions. Since 1911, Lavipharm has a long and successful history of commercial operations in the prescription medicines and self-care products markets in Greece. Globally recognized for its expertise in the development and production of transdermal drug delivery systems (TDDS), Lavipharm has a robust presence in major markets around the world. For over 110 years, Lavipharm has been enabling people to live healthier and longer lives.

###

For further information:
<https://lavipharm.com/>

Lavipharm
Investor Relations
 Tel. +30 210 6691 121
 Email: ir@lavipharm.com

Corporate Communications
 Tel. +30 210 6691 404
 Email: communications@lavipharm.com